Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Advances Key Pipeline Programs and Strengthens Financials

Lexicon Pharmaceuticals reported its first-quarter 2026 financial results and provided key clinical updates across its cardiometabolic pipeline. The company anticipates full enrollment for its pivotal Phase 3 SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy by mid-2026, with topline results expected in Q1 2027. Lexicon is also on track for a mid-2026 NDA resubmission for ZYNQUISTA (sotagliflozin) in type 1 diabetes, with potential for approval this year, pending data from the STENO1 study. Furthermore, Novo Nordisk initiated a Phase 1 study for LX9851 for obesity, triggering a $10 million milestone payment to Lexicon. The company also strengthened its financial position with a recent capital raise and a new $100 million loan facility.

• Lexicon is making significant progress with sotagliflozin, an SGLT1 and SGLT2 inhibitor, in its cardiometabolic pipeline. The pivotal Phase 3 SONATA-HCM trial for hypertrophic cardiomyopathy is expected to complete enrollment by mid-2026, with topline data anticipated in the first quarter of 2027. Concurrently, the company plans to resubmit the New Drug Application (NDA) for ZYNQUISTA in type 1 diabetes by mid-2026, aiming for potential U.S. regulatory approval this year, contingent on patient exposure and safety data from the STENO1 study.
• The partnership with Novo Nordisk for LX9851, a first-in-class ACSL5 inhibitor for obesity and metabolic disorders, is advancing, with Novo Nordisk having initiated a Phase 1 study expected to complete in Q1 2027. This initiation resulted in a $10 million milestone payment to Lexicon, with the potential for an additional $10 million payment later in 2026. The exclusive license agreement could provide Lexicon with up to $1 billion in total payments and tiered royalties on net sales.
• Lexicon reported strong financial results for Q1 2026, with total revenues of $21.1 million, including $20.0 million in milestone revenue. The company's cash, investments, and restricted cash increased to $199.7 million as of March 31, 2026, bolstered by a recent capital raise and a new $100 million loan facility with Hercules Capital. Additionally, the FDA has cleared pilavapadin (LX9211) for Phase 3 development in diabetic peripheral neuropathic pain, with plans for two placebo-controlled, 12-week studies evaluating a 10 mg daily dose.

Sotagliflozin's Broad Potential Across Cardiometabolic Indications

Sotagliflozin's clinical development program extends across multiple cardiometabolic indications beyond hypertrophic cardiomyopathy, with the most advanced programs in diabetes and heart failure. In Type 1 diabetes mellitus, sotagliflozin has been evaluated as adjunct therapy to optimized insulin in the pivotal inTandem1 and inTandem2 studies, using randomized, placebo-controlled designs comparing 200 mg and 400 mg doses against placebo over treatment periods ranging from 14 to 52 weeks. The compound has received approval in the EU for T1DM patients with BMI ≥ 27 kg/m² who have failed to achieve adequate glycemic control despite optimal insulin therapy, though the FDA issued a Complete Response Letter due to diabetic ketoacidosis concerns. For Type 2 diabetes mellitus, the development program has been extended to evaluate sotagliflozin as both monotherapy and add-on therapy to other anti-hyperglycemic agents, with studies demonstrating improvements in glycated hemoglobin alongside beneficial effects on body weight and blood pressure.

Heart failure represents a significant indication for sotagliflozin, which has become the first dual SGLT1/2 inhibitor approved by the FDA for heart failure management. The landmark SOLOIST-WHF trial employed a randomized, placebo-controlled design in patients with T2DM and recent worsening heart failure regardless of ejection fraction, while the SCORED trial evaluated sotagliflozin versus placebo in patients with T2DM, chronic kidney disease, and cardiovascular risk factors using 1:1 randomization. These phase 3 trials demonstrated significant reductions in cardiovascular disease risk and both heart failure outcomes and atherothrombotic events. Additional cardiovascular research includes the SOTA-THROMBOSIS trial, which utilizes a randomized crossover design in healthy volunteers to compare dual SGLT1/2 inhibition with sotagliflozin versus selective SGLT2 inhibition with empagliflozin over 4-week treatment periods separated by one-month washouts.

Emerging preclinical research suggests potential applications in neurodegenerative and metabolic disorders. Molecular docking studies have investigated sotagliflozin's binding affinity to human brain acetylcholinesterase for potential Alzheimer's disease treatment, yielding promising binding parameters (ΔG = -7.16 kcal/mol, Ki = 5.6 μM) that support future drug design based on sotagliflozin scaffolds for Type 3 diabetes. Preclinical models have also demonstrated cardio-renal protective effects in chronic kidney disease using murine subtotal nephrectomy models, while studies in high-fat diet-fed obese mice have shown beneficial effects on liver triglycerides, cholesterol, and inflammatory markers, suggesting therapeutic potential for diabetic dyslipidemia and steatohepatitis. These preclinical intervention models consistently employ controlled animal studies with appropriate comparator groups to evaluate sotagliflozin's broader therapeutic potential across the cardiometabolic spectrum.

Addressing Unmet Needs in Hypertrophic Cardiomyopathy Treatment

Current hypertrophic cardiomyopathy treatment faces multiple challenges despite recent therapeutic advances. These limitations span from diagnostic delays to procedural complications and suboptimal patient selection strategies. The evolving treatment landscape continues to reveal trade-offs between efficacy and safety across different therapeutic modalities.

• High complication rates with implantable cardioverter-defibrillators (ICDs) affect one-third of patients, with inappropriate ICD interventions occurring in 30% due to T-wave oversensing, atrial fibrillation, lead failure, and sinus tachycardia, while pocket infections and lead displacement add to the substantial adverse event burden

• Risk stratification controversies persist in identifying high-risk patients for primary prevention of sudden cardiac death, with ongoing debates about optimal ICD selection criteria despite updated guidelines incorporating left ventricular systolic dysfunction, apical aneurysm, and extensive late gadolinium enhancement as new risk markers

• Treatment trade-offs between septal reduction therapies create difficult clinical decisions, as alcohol septal ablation shows lower peri-procedural complications (5.57% vs. 10.5%) but higher re-intervention rates (10.1% vs. 0.27%) and pacemaker dependency (12.4% vs. 4.31%) compared to surgical myectomy

• Diagnostic delays and misdiagnoses remain common, with HCM often undiagnosed until midlife when symptoms of myocardial remodeling appear, indicating need for enhanced healthcare professional education about atypical HCM presentations

• Substantial disease burden and healthcare resource utilization continues despite current treatments, with 63.2% of patients symptomatic at diagnosis and cardiovascular events occurring 3-60 fold higher than controls, including frequent hospitalizations and emergency visits

• Catheter ablation for atrial fibrillation carries elevated risks in HCM patients, with complications occurring in 16.1% of cases and 1% in-hospital mortality, particularly affecting female, diabetic, and obese patients despite improving procedural techniques over time

SONATA-HCM: Designing a Pivotal Trial for Hypertrophic Cardiomyopathy

The clinical trial landscape for hypertrophic cardiomyopathy has evolved significantly, with recent Phase 3 studies focusing on cardiac myosin inhibitors and metabolic modulators. Key trials have evaluated both obstructive and non-obstructive HCM populations, with endpoints ranging from functional capacity to septal reduction therapy avoidance.

Sotagliflozin's Dual Path: T1D Resubmission and HCM Expansion

Lexicon Pharmaceuticals is navigating a critical period, with its dual SGLT1/SGLT2 inhibitor, sotagliflozin, at the forefront of its strategic initiatives. The company's anticipated mid-2026 NDA resubmission for ZYNQUISTA in type 1 diabetes (T1D) marks a determined effort to enter a market with a clear unmet need for adjunctive oral therapies. While studies consistently show sotagliflozin's ability to reduce HbA1c, insulin dose, and body weight without increasing hypoglycemia in T1D, the persistent concern around diabetic ketoacidosis (DKA) has been a significant hurdle, leading to a previous FDA Complete Response Letter. This resubmission, potentially supported by additional data or risk mitigation strategies, will be closely watched as it could establish a new treatment option for carefully selected T1D patients, particularly those with higher BMI, where benefits may be more pronounced.

Beyond diabetes, sotagliflozin is expanding its therapeutic reach into cardiovascular indications. The ongoing Phase 3 SONATA-HCM study in hypertrophic cardiomyopathy (HCM) represents a significant diversification. The SGLT inhibitor class has demonstrated profound cardiovascular benefits, and a positive outcome in HCM would further solidify sotagliflozin's position as a valuable agent in heart failure management, potentially differentiating it from pure SGLT2 inhibitors by targeting a specific cardiac condition. However, the heart failure market is highly competitive, with well-established SGLT2 inhibitors already demonstrating broad benefits, which could pose a challenge for market adoption.

Lexicon's pipeline validation extends to its early-stage assets, as evidenced by Novo Nordisk's initiation of a Phase 1 study for LX9851 in obesity, triggering a milestone payment. This not only provides non-dilutive funding but also underscores the potential of Lexicon's research capabilities in metabolic diseases. The company's strategic direction appears focused on leveraging its SGLT expertise across a broader cardiometabolic spectrum, but success hinges on overcoming regulatory hurdles for ZYNQUISTA in T1D and delivering positive clinical trial results for its pipeline assets.